| Literature DB >> 30180208 |
María Del Mar Sánchez-Fernández1, Gustavo A Reyes Del Paso1, José Manuel Gil-Cunquero2, María José Fernández-Serrano1.
Abstract
OBJECTIVE: There is evidence of cognitive impairment in patients with end-stage renal disease in hemodialysis (ESRD-HD). However, few studies have exhaustively analyzed executive functions (EFs) in this population, especially considering the influence of a wide range of clinical variables. This study analyzes performance in different EF components in ESRD-HD patients compared to a group of healthy controls (HCs), in addition to the acute effects of HD and the associations of cognitive performance with clinical variables.Entities:
Mesh:
Year: 2018 PMID: 30180208 PMCID: PMC6122819 DOI: 10.1371/journal.pone.0203424
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sociodemographic, biochemical, blood pressure and body composition data as a function of group.
| Variables | ESRD-HD | HC (n = 42) | |||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Age | 51.72 | 9.310 | 51.83 | 6.525 | |
| Years of education | 10.98 | 4.405 | 11.14 | 3.653 | |
| Sex | Male | 81.4 | 69.0 | ||
| Female | 18.6 | 31.0 | |||
| Hours pre-post ev. | 47.67 | 36.47 | 35.31 | 6.61 | |
| Systolic blood pressure | 140.60 | 20.19 | 128.79 | 13.15 | |
| Diastolic blood pressure | 85.85 | 11.76 | 83.76 | 11.78 | |
| Heart rate | 70.34 | 11.06 | 69.51 | 8.40 | |
| BMI | 25.71 | 3.55 | 27.64 | 3.45 | |
| Dry weight kg | 70.45 | 14.27 | 80.04 | 13.52 | |
| Hemoglobin g/dL | 11.74 | 1.46 | 15.18 | 1.12 | |
| Hematocrit % | 35.17 | 4.55 | 45.26 | 3.14 | |
| Albumin g/dL | 3.96 | 0.27 | 4.37 | 0.32 | |
| Ferritin ng/mL | 399.49 | 156.45 | 123.56 | 57.98 | |
| Calcium mg/dL | 9.44 | 1.26 | 9.57 | 0.27 | |
| Phosphorus mg/dL | 4.75 | 1.61 | 3.36 | 0.63 | |
| Sodium mEq/L | 139.52 | 2.56 | 139.96 | 2.34 | |
| Urea mg/dL | 124.33 | 33.49 | 35.40 | 11.04 | |
| Creatinine mg/dL | 9.56 | 2.46 | 0.92 | 0.14 | |
*p < .05
**p < .001
Note: Abbreviations and definitions: ESRD-HD: end-stage renal disease undergoing hemodialysis; HC: healthy control; Hours pre-post ev.: hours elapsed between pre- and post-evaluations; BMI: body mass index; Dry weight: ideal weight of individual with no excess fluid in blood.
Clinical characteristics of the ESRD-HD group.
| Variables | ESRD-HD | |
|---|---|---|
| Mean | SD | |
| Current months HD | 42.00 | 61.53 |
| Previous TX, | 17 (39.53) | |
| Total months TX | 42.53 | 81.04 |
| Total months HD | 58.88 | 70.25 |
| Total months PD | 4 | 10.46 |
| Total months D | 62.88 | 68.32 |
| Total months RRT | 105.42 | 114.56 |
| Total Kt/v | 1.69 | 0.41 |
| Pre-HD hours | 56.56 | 5.34 |
| Post-HD hours | 20.84 | 2.83 |
| Diabetic patients, | 3 (6.98) | |
| Hypertension patients, | 38 (88.37) | |
| Glomerulonephritis | 17 (39.5) | |
| Interstitial | 2 (4.7) | |
| Hereditary | 10 (23.3) | |
| Vascular | 5 (11.6) | |
| Systemic | 2 (4.7) | |
| Miscellaneous | 1 (2.3) | |
| Diabetic | 1 (2.3) | |
| Unknown | 5 (11.6) | |
Note: Abbreviations and definitions: ESRD-HD: end-stage renal disease undergoing hemodialysis; current months HD: number of months under current HD treatment; Previous TX, n(%): total number (and percentage) of patients previously transplanted; Total months TX: total number of previous months in transplantation; Total months HD: total number of months under hemodialysis; Total months PD: total number of months under peritoneal dialysis; Total months D: total number of months under dialysis treatment (HD and/or PD); Total months RRT: total number of months under renal replacement therapy (hemodialysis, peritoneal dialysis, transplantation); Total Kt/v: calculated with the second-generation Daugirdas formula; Pre-HD hours: hours elapsed since most recent HD in the pre-HD evaluation; post-HD hours: hours since most recent HD in the post-HD evaluation.
Fig 1Cohen’s d values for group comparison of the dependent variables (the order of the tests in the figure follows their administration sequence).
Means (±SD), median, and 25th and 75th percentiles of neuropsychological variables for the two groups in the pre-HD evaluation.
| Dominion | Dep. Variables | Group | Mean±SD | Median | F | p | |
|---|---|---|---|---|---|---|---|
| 30.19±7.65 | 28 [25–35] | 10.51 | 0.002 | 0.117 | |||
| 35.12±7.64 | 34 [30–40.25] | ||||||
| 27.74±12.80 | 25 [19–34] | 22.01 | <0.001 | 0.218 | |||
| 37.93±10.26 | 40 [28–46.25] | ||||||
| 68.26±19.66 | 68 [50–85] | 2.76 | 0.100 | 0.034 | |||
| 75.69±19.25 | 75.50 [67.25–90.25] | ||||||
| 7.91±3.02 | 8 [6–10] | 6.46 | 0.013 | 0.076 | |||
| 9.45±2.84 | 9 [7.75–11] | ||||||
| 10.70±3.16 | 10 [8–13] | 10.18 | 0.002 | 0.114 | |||
| 12.83±3.61 | 13 [10–15.25] | ||||||
| 15.21±5.29 | 16 [13–19] | 3.89 | 0.052 | 0.047 | |||
| 17.48±5.22 | 17 [13.75–22.25] | ||||||
| 18.17±7.32 | 17 [13–23] | 7.33 | 0.008 | 0.085 | |||
| 14.89±5.68 | 15 [11.37–18.12] | ||||||
| 38.73±16.61 | 36 [25–52.50] | 6.87 | 0.011 | 0.080 | |||
| 31.30±14.16 | 29 [22.50–36.25] | ||||||
| 20.95±13.71 | 19 [11–27] | 3.64 | 0.06 | 0.044 | |||
| 15.86±9.31 | 13 [9–22] | ||||||
| -1.12±7.49 | -2 [–6–4] | 4.85 | 0.030 | 0.058 | |||
| 5.79±15.67 | 4.50 [-6.50–14] | ||||||
| 1.63±1.79 | 1 [0–4] | 1.95 | 0.166 | 0.024 | |||
| 2.21±1.47 | 2 [1–4] |
Note: Results of group comparisons after controlling for age, years of education, mood and blood pressure are also included. ESRD-HD: end-stage renal disease undergoing hemodialysis; HC: healthy control.
Means (±SD) of the pre- and post- cognitive evaluations and statistics for the main repeated measures factor.
| Domain | Dep. Variables | Group | Mean±SD Pre- | Mean±SD Post | F (1,83) | p | Ƞ2p |
|---|---|---|---|---|---|---|---|
| 30.19± 7.65 | 33.51±9.17 | 24.48 | <0.001 | 0.228 | |||
| 35.12± 7.64 | 37.31 ±6.21 | ||||||
| 27.74±12.80 | 31.98±12.46 | 28.99 | <0.001 | 0.259 | |||
| 37.93±10.26 | 40.29±10.39 | ||||||
| 68.26±19.66 | 80.65±25.60 | 114.48 | <0.001 | 0.580 | |||
| 75.69±19.25 | 89.83±22.75 | ||||||
| 7.91± 3.02 | 8.30± 2.83 | 8.81 | 0.01 | 0.096 | |||
| 9.45± 2.84 | 10.26±3.17 | ||||||
| 10.70±3.16 | 12.16±3.66 | 19.47 | <0.001 | 0.190 | |||
| 12.83±3.615 | 13.29±4.06 | ||||||
| 15.21±5.29 | 15.98±4.82 | 4.01 | 0.04 | 0.046 | |||
| 17.48±5.22 | 17.81±5.19 | ||||||
| 18.17±7.32 | 14.14±6.36 | 21.41 | <0.001 | 0.205 | |||
| 14.89±5.68 | 13.74±4.91 | ||||||
| 38.73±16.61 | 27.19±14.46 | 91.51 | <0.001 | 0.524 | |||
| 31.30±14.16 | 22.50±10.01 | ||||||
| 20.95±13.71 | 15.83±12.01 | 23.08 | <0.001 | 0.220 | |||
| 15.86±9.31 | 11.79±8.55 | ||||||
| 1.63±1.79 | 1.81±1.68 | 4.81 | 0.03 | 0.055 | |||
| 2.21±1.47 | 2.36±1.48 |
Note: ESRD-HD: End-stage renal disease undergoing hemodialysis; HC: healthy control. Only variables that showed significant changes were displayed.